Shandong Xinhua (00719) received the "Drug Supplement Application Approval Notice" for Rosuvastatin Calcium Tablets (20mg; 10mg)
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced that recently, the company has received approval and issuance of the Ruishu...
SHANDONG XINHUA (00719) announced that recently the company received the approval notification from the National Medical Products Administration for the transfer of the marketing authorization application of rosuvastatin calcium tablets (20mg;10mg).
The rosuvastatin calcium tablets (20mg;10mg) were approved by the National Medical Products Administration in January 2025, and Shandong Xinhua Pharmaceutical became the marketing authorization holder for this product. The market launch of this product will help enrich the company's product line of statin lipid-regulating drugs and enhance the company's overall competitive advantage.
Related Articles
US Stock Market Move | Target Corporation (TGT.US) rose more than 4% as first-quarter results exceeded expectations and full-year guidance was raised.
MAANSHAN IRON (00323) plans to increase capital in Baowu Environmental Science by using its equity in Baowu Water to deepen the synergy of green industries.
US Stock Market Move | Estee Lauder Companies Inc. Class A (EL.US) rose nearly 6%, Citigroup raised its target price to $110.
US Stock Market Move | Target Corporation (TGT.US) rose more than 4% as first-quarter results exceeded expectations and full-year guidance was raised.
MAANSHAN IRON (00323) plans to increase capital in Baowu Environmental Science by using its equity in Baowu Water to deepen the synergy of green industries.
US Stock Market Move | Estee Lauder Companies Inc. Class A (EL.US) rose nearly 6%, Citigroup raised its target price to $110.
